Individualized Dosing of Enoxaparin for Subjects With Renal Impairment Is Superior to Conventional Dosing at Achieving Therapeutic Concentrations
- 1 August 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 32 (4), 482-488
- https://doi.org/10.1097/ftd.0b013e3181e64846
Abstract
Enoxaparin is an anticoagulant used in the treatment of thromboembolic diseases. It is a hydrophilic molecule that is, predominantly, eliminated renally with few data to support dosing for subjects with renal impairment and/or obesity. A recently conducted randomized controlled clinical trial compared individualized enoxaparin doses based on lean body weight and renal function to conventional dosing. During this trial, anti-Xa concentrations were collected using a sparse sampling design and a population pharmacokinetic model was developed to describe the data. The current study evaluated the ability of the individualized dose to achieve and maintain anti-Xa concentrations within the therapeutic range (0.5-1.0 IU/mL) in subjects with renal impairment and/or obesity. A matched comparison of the two dosing strategies was undertaken using individual model predicted anti-Xa concentrations generated every 30 minutes to 120 hours post initiation of therapy. Concentration-time curves were generated for each subject and the proportion of time in the therapeutic, supratherapeutic, and subtherapeutic ranges were determined. When compared with conventional dosing, individualized dosing in subjects with renal impairment resulted in a significantly greater proportion of time in the therapeutic range (median [range] = 69.9% (11.3-91.8) versus 42.6% [13.9-71.4], P = 0.02) and a significantly reduced proportion of time in the supratherapeutic range (median [range] = 9.3% (0%-67.0%) versus 37.1% (0%-85.7%), P = 0.02). Although there was a trend toward a greater proportion of time in the therapeutic range in obese subjects, this did not achieve statistical significance. Individualized dosing in subjects with renal impairment is more effective than conventional dosing at achieving and maintaining therapeutic anti-Xa concentrations, which could decrease the risk of bleeding events and mortality in these subjects.Keywords
This publication has 23 references indexed in Scilit:
- Individualized Compared With Conventional Dosing of EnoxaparinClinical Pharmacology & Therapeutics, 2007
- Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromesBritish Journal of Clinical Pharmacology, 2005
- Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With EnoxaparinCirculation, 2004
- Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled TrialJAMA, 2004
- Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary EmbolismAnnals of Internal Medicine, 2004
- Development of a dosing strategy for enoxaparin in obese patientsBritish Journal of Clinical Pharmacology, 2003
- Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic DiseaseAnnals of Internal Medicine, 2001
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseThe New England Journal of Medicine, 1997
- Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11AJournal of the American College of Cardiology, 1997